No Data
12 Health Care Stocks Moving In Wednesday's Intraday Session
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 P.m. ET
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Constantine Davides maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 23.5%
OptimizeRx: A Strong Buy on Client Commitments and Growth Potential
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
Lake Street analyst Eric Martinuzzi maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 40.9% and a
No Data
No Data